Search

Displaying results 2801 - 2810 of 10000 in total
  1. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    US in December 2021. … Atopic dermatitis (AD) is an inflammatory skin disorder that causes skin inflammation, skin barrier dysfunction, and chronic pruritus.

  2. Drug

    Levotofisopam

    go.drugbank.com/drugs/DB19073
    Investigational

    Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).

  3. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … restricted expression on normal tissues.

  4. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    effects (Kovoor et al, 2009). … Levoleucovorin, as the product Fusilev (FDA), has an additional indication for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal

    Synonyms: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidCategories: Compounds used in a research, industrial, or household setting, Vitamin B Complex
  5. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

  6. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    [A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal; it was granted a new FDA approval on June 25, 2020, for treatment of patients with Dravet syndrome … from the market in 1997.

    Synonyms: 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane
  7. Drug

    Cobomarsen

    go.drugbank.com/drugs/DB14931
    Investigational

    Cobomarsen is under investigation in clinical trial NCT02580552 (Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL).

  8. Indication

    Ventricular Ectopic Beat

    go.drugbank.com/conditions/DBCOND0120769
    Drugs: Hydroquinidine
    Synonyms: Ventricular premature complex, Premature Ventricular Complex
  9. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    Axatilimab is a humanized IgG4 monoclonal antibody produced in Chinese hamster ovary cells. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  10. Drug

    Triheptanoin

    go.drugbank.com/drugs/DB11677
    ApprovedInvestigational

    [A214817] Triheptanoin was granted FDA approval on 30 June 2020.[L14612] … [A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin.